Verkkothis milestone bolsters the availability of grifols’ plasma therapies; Verkkothe flagship grifols campus is a touchstone of grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output. Verkkothe transaction bolsters grifols’ standing as a global leader in fractionation capacity (20 million liters plasma/year) and operator of europe’s largest. Verkkoin an interview by xtalks, jörg schüttrumpf, chief scientific innovation officer (csio) at grifols, sheds light on the company's commitment to innovation in.

Understanding the Context